Huw holds a PhD in pharmacology from the University of Birmingham, UK and has over thirty years experience in the pharmaceutical and biotechnology sectors. He has built several start-up companies and delivered development plans in a wide range of therapy areas.
He has supervised over fifteen product launches in Europe and has completed numerous product and company acquisitions and divestments.
As a founding partner of Daffodil Consulting LLP, Huw has advised many biotech companies on US and EU development, pricing and re-imbursement and commercialisation. He was a director of Ardana plc. and was previously President, Europe for CV Therapeutics Inc. Other appointments include Chairman, Ashbourne Pharmaceuticals, Senior Vice President, Northern Europe, for Elan Pharmaceuticals, building European operations from a start-up to a 600 person division, and UK marketing director for SmithKlineBeecham Pharmaceuticals, now part of GlaxoSmithKline plc.
Huw is also strategic advisor to Gen2 Neuroscience, a Dementia Discovery Fund company based in Cambridge, UK and a non-executive director of cell therapy company Rexgenero Ltd.